figshare
Browse
13045_2021_1140_MOESM3_ESM.docx (18.35 kB)

Additional file 3 of Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

Download (18.35 kB)
journal contribution
posted on 2021-08-24, 03:50 authored by Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu, Lingyan Ping, Zongliang Liu, Hanying Bao, Zusheng Xu, Lugui Qiu
Additional file 3. Table S2: Basic characteristics of patients in each group.

Funding

Shanghai Yingli Pharmaceutical Co., Ltd. Biomedical Science and Technology Support Program of Shanghai Science and Technology Commission

History

Usage metrics

    Journal of Hematology & Oncology

    Categories

    Keywords

    LinperlisibPI3Kδ inhibitorDose-limiting toxicityNon-Hodgkin’s lymphomaPharmacokinetics

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC